California Made a Big Bet on Producing Its Own Insulin, But There’s No ‘Date Certain’ for Delivery
During a hearing, representatives for the Newsom administration said they could not provide a timeline for when ...
Weight loss drugs at home: the controversial idea from the creator of Ozempic that is triumphing in the United States
Danish pharmaceutical company Novo Nordisk turned the market upside down when it launched Ozempic, a diabetes drug that ended ...
Novo Nordisk, Sanofi Face South Africa Insulin Antitrust Probe
Novo Nordisk A/S and Sanofi are facing an investigation in South Africa over concerns about potential anti-competitive practices in the human insulin pen market.
Novo Nordisk to explore how GLP-1 drugs can help patients with addiction
Novo Nordisk will explore how GLP-1 drugs could help patients struggling with addiction, its head of development Martin Holst ...
Medical Marketing & Media2d
Novo Nordisk welcomes patients to the Ozempic Era
With semaglutide shortages in the rearview, Novo Nordisk is doubling down on marketing efforts for its GLP-1 drugs.
Novo Nordisk Joins Legal Battle Over Weight Loss Drug Shortage
Novo Nordisk A/S can intervene in a lawsuit between the FDA and drug compounders over whether its blockbuster drugs Wegovy ...
Yahoo Finance4d
Novo Nordisk Plunges 21% in 3 Months: Buy, Sell or Hold the Stock?
Novo Nordisk NVO shares have lost 21% in the past ... Lilly also markets tirzepatide under the brand name, Mounjaro, for type II diabetes (T2D). Another factor that has likely contributed to ...
Independent Online5d
South African Competition Commission probes Novo Nordisk and Sanofi over insulin pen market
Novo Nordisk A/S and Sanofi are facing an investigation in South Africa over concerns about potential anti-competitive practices in the human insulin pen market. South Africa’s Competition ...